Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 10/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701793 | 0.85 | USP2 (0.37) | WNT3AUSP30SYKCTSSCTSK | |
| SCHEMBL4700970 | 0.83 | CYP1A2 (0.43) | CTSSCTSK | |
| SCHEMBL4701375 | 0.83 | SYK (0.35) | WNT3ASYKCTSSCTSK | |
| SCHEMBL4698764 | 0.83 | WNT3A (0.36) | WNT3ASYKCTSSCTSKPRKD1 | |
| SCHEMBL4699920 | 0.80 | CTSK (0.40) | WNT3ACTSSCTSK | |
| SCHEMBL4701773 | 0.80 | WNT3A (0.36) | WNT3ASYKJAK2 | |
| SCHEMBL4703005 | 0.79 | SYK (0.36) | WNT3ASYKCTSSCTSKJAK2 | |
| SCHEMBL4699833 | 0.79 | CTSS (0.44) | CTSSCTSKPRKD1 | |
| SCHEMBL4699879 | 0.79 | SYK (0.35) | WNT3ASYKJAK2 | |
| SCHEMBL4702478 | 0.79 | SYK (0.37) | WNT3AUSP30SYKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372655-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-10-01 | — | — | EP | claimed |
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | claimed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | claimed |
| EP-1372655-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-10-01 | — | — | EP | disclosed |
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | WNT3A 3276/4885USP30 617/4885KIT 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.